Skip to main content

Pharma Available

Wegovy Weight Management

Wegovy Weight Loss Treatment

A once-weekly prescription treatment containing semaglutide, available following an individual clinical assessment.

Treatment Overview

What Is Wegovy?

Wegovy is a prescription weight-management medicine containing semaglutide.

Semaglutide is similar to the natural GLP-1 hormone released after eating. It acts on appetite-regulating receptors in the brain and may help you feel fuller, less hungry and experience fewer food cravings.

Wegovy is normally injected once weekly and should be used alongside a reduced-calorie eating plan, increased physical activity and ongoing clinical monitoring.

01
Active IngredientSemaglutide
02
Treatment TypeOnce-weekly injection
03
Starting DoseUsually 0.25 mg weekly
04
Standard MaintenanceUsually 2.4 mg weekly
05
Pen FormatMulti-dose FlexTouch pen
06
Clinical ReviewRequired before approval
Completing an assessment does not guarantee that Wegovy will be prescribed or supplied.
Once WeeklyUse on the prescribed day
Clinically ReviewedIndividual suitability assessment
How It Works

How Can Wegovy Support Weight Management?

Wegovy acts like the natural GLP-1 hormone and influences appetite signals in the brain. This may help you eat less as part of a wider clinically managed plan.

01
Supports Appetite Control

May reduce hunger between meals.

02
Increases Fullness

May help you feel satisfied sooner after eating.

03
Reduces Food Cravings

May reduce the intensity of appetite-related cravings.

GLP-1 Appetite pathway
Treatment Eligibility

Could Wegovy Be Suitable for You?

Wegovy may be considered for adults with a BMI of 30 kg/m² or above, or a BMI from 27 kg/m² to below 30 kg/m² together with at least one weight-related health condition.

Check My Suitability
What the pharmacist reviewsA complete clinical assessment
Height, weight and BMI Weight-related health conditions Current medicines and allergies Previous weight-management treatment Diabetes medicines and blood-sugar risk Digestive, gallbladder or pancreatic history Pregnancy and breastfeeding Lifestyle and treatment goals
Meeting general BMI criteria does not automatically mean that Wegovy is suitable for you.
Treatment Safety

Side Effects and Important Safety Information

Wegovy can cause side effects and is not suitable for everyone. Every accordion is closed when the page first loads.

Very common effects include nausea, vomiting, diarrhoea, constipation, abdominal pain, headache and fatigue. Indigestion, reflux, bloating, dizziness and injection-site reactions may also occur.

Smaller meals, slower eating, avoiding rich or high-fat food and maintaining adequate hydration may help. Contact the pharmacist when symptoms are persistent, worsening or difficult to manage.

Disclose any history of pancreatitis, gallstones, severe digestive problems, kidney disease, diabetic eye disease, low blood sugar, upcoming surgery or anaesthesia, and use of insulin, sulphonylureas or another GLP-1 medicine.

Wegovy should not be used during pregnancy or breastfeeding. It should be stopped at least two months before a planned pregnancy because semaglutide remains in the body for a prolonged period.

Seek urgent help for severe persistent abdominal pain, signs of a serious allergic reaction, sudden loss or rapid worsening of vision, severe dehydration or rapidly worsening symptoms.

Do not increase, reduce or stop Wegovy without professional guidance.
Safety Comes FirstRead the leaflet supplied with your medicine
Supporting Your Treatment

Wegovy Works Best with Sustainable Habits

Medication forms one part of a longer-term weight-management plan. Nutrition, movement, hydration and progress reviews remain important.

Balanced Nutrition

Build meals around suitable portions, protein, fibre and nutritious food choices.

Regular Movement

Increase activity gradually according to your health, ability and clinical advice.

Hydration

Maintain fluid intake, especially when nausea, vomiting or diarrhoea occurs.

Progress Reviews

Monitor weight, appetite, side effects, eating patterns and overall wellbeing.

Ongoing treatment should remain beneficial and clinically appropriate.

Progress and safety may be reviewed before repeat treatment is approved.

Start Wegovy Assessment
Wegovy Questions

Wegovy Frequently Asked Questions

Clear answers about weekly use, dosing, switching, pregnancy and treatment approval.

Yes. Wegovy is normally injected once weekly, preferably on the same day each week.

The standard FlexTouch escalation pathway normally begins at 0.25 mg once weekly before gradual dose increases.

Dose progression depends on tolerance, side effects and clinical advice. Do not increase the dose yourself.

Results vary and cannot be guaranteed. Progress depends on individual response, adherence, nutrition, activity and health factors.

A switch may be considered after a new clinical assessment. Never combine or switch treatments without prescriber guidance.

No. Wegovy should not be used during pregnancy and should be stopped at least two months before a planned pregnancy.

The pharmacist may recommend another option, request more information or advise you to contact your GP or another service.

No. Wegovy is supplied only after the pharmacist confirms that it is clinically suitable and appropriate.

Start Your Wegovy Journey

Could Wegovy Be Right for You?

Complete a confidential online assessment and let our pharmacy professional review whether Wegovy may be suitable for your health, circumstances and weight-management goals.

✓ Confidential assessment✓ Individual pharmacist review✓ Responsible prescribing✓ Discreet delivery
Wegovy is a prescription-only medicine. Supply is subject to clinical suitability, verification, availability and pharmacist approval. Results vary and cannot be guaranteed.